

Robert P Hasserjian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6105623/publications.pdf>

Version: 2024-02-01

141
papers

14,379
citations

182225

30
h-index

25230

113
g-index

149
all docs

149
docs citations

149
times ranked

15701
citing authors

#	ARTICLE	IF	CITATIONS
1	Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. <i>Blood</i> , 2022, 139, 323-332.	0.6	80
2	Global Cytopathology-Hematopathology Practice Trends. <i>American Journal of Clinical Pathology</i> , 2022, 157, 196-201.	0.4	4
3	Lymph node FNA cytology: Diagnostic performance and clinical implications of proposed diagnostic categories. <i>Cancer Cytopathology</i> , 2022, 130, 144-153.	1.4	8
4	This Year's Best in Hematology Diagnosis: A New Disease Is Discovered. , 2022, 19, .		2
5	<i>TP53</i> mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. <i>Blood Advances</i> , 2022, 6, 2847-2853.	2.5	87
6	Primary Central Nervous System Anaplastic Large Cell Lymphoma, ALK Positive. <i>American Journal of Clinical Pathology</i> , 2022, 158, 300-310.	0.4	4
7	Survival of the Fittest: Hypomethylating Agent/BCL-2 Inhibitor Combination Versus Intensive Chemotherapy As Frontline Treatment for Acute Myeloid Leukemia. , 2022, 19, .		0
8	Bedside to Bench and Back: Identifying a New Clinically Relevant Driver in Pediatric Acute Myeloid Leukemia. <i>Blood Cancer Discovery</i> , 2022, , .	2.6	1
9	Guiding the global evolution of cytogenetic testing for hematologic malignancies. <i>Blood</i> , 2022, 139, 2273-2284.	0.6	29
10	<i>TP53</i> -mutated Acute Myeloid Leukemia and Myelodysplastic Syndrome With Excess Blasts: Two Sides of the Same Coin?. , 2022, 19, .		0
11	ALK-positive Histiocytosis: An Old Target Shows Up in a New Disguise. , 2022, 19, .		0
12	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, .		259
13	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. <i>Blood</i> , 2022, 140, 1200-1228.	0.6	814
14	Revealing the dark secrets of <i>TP53</i> -mutated AML. <i>Blood</i> , 2022, 140, 8-10.	0.6	2
15	Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. <i>Blood</i> , 2022, 140, 1345-1377.	0.6	805
16	Genomic alterations in patients with somatic loss of the Y chromosome as the sole cytogenetic finding in bone marrow cells. <i>Haematologica</i> , 2021, 106, 555-564.	1.7	34
17	Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1. <i>Modern Pathology</i> , 2021, 34, 20-31.	2.9	9
18	Ocular adnexal lymphoma: long-term outcome, patterns of failure and prognostic factors in 174 patients. <i>Journal of Hematopathology</i> , 2021, 14, 41-52.	0.2	1

#	ARTICLE	IF	CITATIONS
19	Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group. <i>Modern Pathology</i> , 2021, 34, 1358-1366.	2.9	8
20	Flow cytometry reveals the nuances of clonal haematopoiesis. <i>British Journal of Haematology</i> , 2021, 192, 949-950.	1.2	1
21	JAK2 Rearrangements Are a Recurrent Alteration in CD30+ Systemic T-Cell Lymphomas With Anaplastic Morphology. <i>American Journal of Surgical Pathology</i> , 2021, 45, 895-904.	2.1	29
22	Navigating Myelodysplastic and Myelodysplastic/Myeloproliferative Overlap Syndromes. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 328-350.	1.8	2
23	Controversies in the recent (2016) World Health Organization classification of acute myeloid leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101249.	0.7	9
24	A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML. <i>Blood Advances</i> , 2021, 5, 2279-2283.	2.5	2
25	Multiorgan failure in a fatal case of autoimmune hemolytic anemia. <i>Transfusion</i> , 2021, 61, 2795-2798.	0.8	3
26	Myeloid/lymphoid neoplasms with FLT3 rearrangement. <i>Modern Pathology</i> , 2021, 34, 1673-1685.	2.9	21
27	Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML. <i>Blood Advances</i> , 2021, 5, 2539-2549.	2.5	9
28	The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13. <i>Blood</i> , 2021, 138, 1870-1884.	0.6	20
29	Myelodysplastic syndromes with no somatic mutations detected by next-generation sequencing display similar features to myelodysplastic syndromes with detectable mutations. <i>American Journal of Hematology</i> , 2021, 96, E420-E423.	2.0	5
30	Erythroid nuclear dysplasia is associated with inferior outcomes for patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia Research</i> , 2021, 109, 106625.	0.4	0
31	Case 33-2021: A 68-Year-Old Man with Painful Mouth Ulcers. <i>New England Journal of Medicine</i> , 2021, 385, 1700-1710.	13.9	1
32	TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes. <i>Cancers</i> , 2021, 13, 5502.	1.7	2
33	Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. <i>Modern Pathology</i> , 2021, , .	2.9	9
34	Changes in ABC Transporter Expression during Hematopoiesis Cause Lineage-Biased Cytopenias in Patients Treated with Aurora Kinase Inhibitors. <i>Blood</i> , 2021, 138, 4292-4292.	0.6	0
35	Oligoblastic ($\leq 20\%$) Myeloid Neoplasms with KMT2A (MLL) Rearrangement Show Significant Overlap with Acute Myeloid Leukemia (AML) and Should be Regarded As AML. <i>Blood</i> , 2021, 138, 793-793.	0.6	1
36	A phase 1 study of the antibody-drug conjugate brentuximab vedotin with induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia. <i>Cancer</i> , 2020, 126, 1264-1273.	2.0	15

#	ARTICLE	IF	CITATIONS
37	Detection of the KITD816V mutation in myelodysplastic and/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosis. <i>Modern Pathology</i> , 2020, 33, 1135-1145.	2.9	12
38	Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis. <i>Blood</i> , 2020, 136, 3051-3055.	0.6	15
39	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. <i>Nature Medicine</i> , 2020, 26, 1549-1556.	15.2	372
40	Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia. <i>Blood</i> , 2020, 135, 1729-1738.	0.6	80
41	Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with increased blasts ($\leq 10\%$) or with other types of disease progression. <i>Haematologica</i> , 2020, 105, e221-e224.	1.7	8
42	How I Diagnose Low-Grade Myelodysplastic Syndromes. <i>American Journal of Clinical Pathology</i> , 2020, 154, 5-14.	0.4	9
43	Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1 and VIM KMT2A fusions. <i>Modern Pathology</i> , 2020, 33, 2307-2317.	2.9	24
44	Bone marrow niches in haematological malignancies. <i>Nature Reviews Cancer</i> , 2020, 20, 285-298.	12.8	270
45	Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2020, 34, 2025-2037.	3.3	27
46	Multiparametric in situ imaging of NPM1-mutated acute myeloid leukemia reveals prognostically-relevant features of the marrow microenvironment. <i>Modern Pathology</i> , 2020, 33, 1380-1388.	2.9	9
47	On-chip recapitulation of clinical bone marrow toxicities and patient-specific pathophysiology. <i>Nature Biomedical Engineering</i> , 2020, 4, 394-406.	11.6	170
48	Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study. <i>American Journal of Hematology</i> , 2020, 95, 799-808.	2.0	26
49	Concordance among hematopathologists in classifying blasts plus promonocytes: A bone marrow pathology group study. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 418-422.	0.7	21
50	Identification of germline variants in adults with hemophagocytic lymphohistiocytosis. <i>Blood Advances</i> , 2020, 4, 925-929.	2.5	8
51	The current approach to the diagnosis of myelodysplastic syndromes†. <i>Seminars in Hematology</i> , 2019, 56, 15-21.	1.8	22
52	Composite chronic myeloid leukemia and essential thrombocythemia with BCR-ABL1 fusion and CALR mutation. <i>American Journal of Hematology</i> , 2019, 94, 504-505.	2.0	9
53	Premalignant Clonal Hematopoietic Proliferations. <i>American Journal of Clinical Pathology</i> , 2019, 152, 347-358.	0.4	3
54	Genetic Testing in the Diagnosis and Biology of Myeloid Neoplasms (Excluding Acute Leukemias). <i>American Journal of Clinical Pathology</i> , 2019, 152, 302-321.	0.4	5

#	ARTICLE	IF	CITATIONS
55	High <i>NPM1</i> mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, 921-928.	2.0	24
56	Gene expression profiling distinguishes prefibrotic from overtly fibrotic myeloproliferative neoplasms and identifies disease subsets with distinct inflammatory signatures. <i>PLoS ONE</i> , 2019, 14, e0216810.	1.1	20
57	Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. <i>Modern Pathology</i> , 2019, 32, 1373-1385.	2.9	25
58	Characterization of applicants for residency training in pathology: Does diversity exist?. <i>Annals of Diagnostic Pathology</i> , 2019, 40, 23-25.	0.6	3
59	lluminating neutrophilic myeloid neoplasms. <i>Blood</i> , 2019, 134, 846-848.	0.6	6
60	Clinicopathologic and genetic characterization of nonacute <i>NPM1</i> -mutated myeloid neoplasms. <i>Blood Advances</i> , 2019, 3, 1540-1545.	2.5	44
61	Blast phenotype and comutations in acute myeloid leukemia with mutated <i>NPM1</i> influence disease biology and outcome. <i>Blood Advances</i> , 2019, 3, 3322-3332.	2.5	20
62	Clinicopathological and molecular features of <i>SF3B1</i> -mutated myeloproliferative neoplasms. <i>Human Pathology</i> , 2019, 86, 1-11.	1.1	24
63	Hematopoietic neoplasms with 9p24/ <i>JAK2</i> rearrangement: a multicenter study. <i>Modern Pathology</i> , 2019, 32, 490-498.	2.9	50
64	<i>TP53</i> State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes. <i>Blood</i> , 2019, 134, 675-675.	0.6	17
65	Bone Marrow Morphologic Findings in Patients Receiving <i>IDH</i> Inhibitor Therapy in Combination with Intensive Induction Chemotherapy: Challenges with Interpretation of the Day 14 Bone Marrow Biopsy. <i>Blood</i> , 2019, 134, 1442-1442.	0.6	0
66	A reevaluation of erythroid predominance in Acute Myeloid Leukemia using the updated WHO 2016 Criteria. <i>Modern Pathology</i> , 2018, 31, 873-880.	2.9	3
67	A distinct immunophenotype identifies a subset of <i>NPM1</i> -mutated AML with <i>TET2</i> or <i>IDH1/2</i> mutations and improved outcome. <i>American Journal of Hematology</i> , 2018, 93, 504-510.	2.0	36
68	Changes in the World Health Organization 2016 classification of myeloid neoplasms everyone should know. <i>Current Opinion in Hematology</i> , 2018, 25, 120-128.	1.2	4
69	Association of mutations with morphological dysplasia in de novo acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities. <i>Haematologica</i> , 2018, 103, 626-633.	1.7	20
70	High <i>NPM1</i> -mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. <i>Blood</i> , 2018, 131, 2816-2825.	0.6	64
71	<i>JAK2</i> , <i>CALR</i> , <i>MPL</i> and <i>ASXL1</i> mutational status correlates with distinct histological features in Philadelphia chromosome-negative myeloproliferative neoplasms. <i>Haematologica</i> , 2018, 103, e63-e68.	1.7	13
72	<i>tp53</i> deficiency causes a wide tumor spectrum and increases embryonal rhabdomyosarcoma metastasis in zebrafish. <i>ELife</i> , 2018, 7, .	2.8	51

#	ARTICLE	IF	CITATIONS
73	Nuclear IHC enumeration: A digital phantom to evaluate the performance of automated algorithms in digital pathology. PLoS ONE, 2018, 13, e0196547.	1.1	7
74	JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group. British Journal of Haematology, 2018, 182, 78-85.	1.2	22
75	Diagnostic algorithm for lower-risk myelodysplastic syndromes. Leukemia, 2018, 32, 1679-1696.	3.3	10
76	PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study. Blood, 2018, 132, 686-686.	0.6	44
77	Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Myeloid Leukemia. Blood, 2018, 132, 1431-1431.	0.6	0
78	Clinical, Immunophenotypic and Genomic Findings of Acute Undifferentiated Leukemia and Comparison to AML with Minimal Differentiation: A Study from the Bone Marrow Pathology Group. Blood, 2018, 132, 1491-1491.	0.6	0
79	Clinicopathologic evaluation of cytopenic patients with isolated trisomy 8: a detailed comparison between idiopathic cytopenia of unknown significance and low-grade myelodysplastic syndrome. Leukemia and Lymphoma, 2017, 58, 569-577.	0.6	12
80	Prognostic Significance of Residual Acute Myeloid Leukemia in Bone Marrow Samples Taken Prior to Allogeneic Hematopoietic Cell Transplantation. American Journal of Clinical Pathology, 2017, 147, aqw203.	0.4	2
81	Computer-assisted quantification of CD3+ T cells in follicular lymphoma. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2017, 91, 609-621.	1.1	5
82	Assessment of myeloid and monocytic dysplasia by flow cytometry in de novo AML helps define an AML with myelodysplasia-related changes category. Journal of Clinical Pathology, 2017, 70, 109-115.	1.0	7
83	Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. Haematologica, 2017, 102, 1352-1360.	1.7	62
84	Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 30 chronic myelomonocytic leukemia. Modern Pathology, 2017, 30, 1213-1222.	2.9	52
85	Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis. American Journal of Clinical Pathology, 2017, 148, 49-57.	0.4	18
86	NPM1 mutation but not RUNX1 mutation or multilineage dysplasia defines a prognostic subgroup within de novo acute myeloid leukemia lacking recurrent cytogenetic abnormalities in the revised 2016 WHO classification. American Journal of Hematology, 2017, 92, E123-E124.	2.0	11
87	Ring chromosome in myeloid neoplasms is associated with complex karyotype and disease progression. Human Pathology, 2017, 68, 40-46.	1.1	5
88	European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia. American Journal of Hematology, 2017, 92, 1062-1067.	2.0	33
89	Most Myeloid Neoplasms With Deletion of Chromosome 16q Are Distinct From Acute Myeloid Leukemia With Inv(16)(p13.1q22). American Journal of Clinical Pathology, 2017, 147, 411-419.	0.4	6
90	Primary lymphoma of bone in the pediatric and young adult population. Human Pathology, 2017, 60, 1-10.	1.1	31

#	ARTICLE	IF	CITATIONS
109	Acute myeloid leukemia in a patient with constitutional 47,XXY karyotype. <i>Leukemia Research Reports</i> , 2015, 4, 28-30.	0.2	0
110	Impact of Bone Marrow Pathology on the Clinical Management of Philadelphia Chromosome-“Negative Myeloproliferative Neoplasms. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 253-261.	0.2	16
111	Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. <i>Blood</i> , 2015, 126, 9-16.	0.6	1,493
112	Chronic lymphocytic leukemia/small lymphocytic lymphoma: another neoplasm related to the B-cell follicle?. <i>Leukemia and Lymphoma</i> , 2015, 56, 3378-3386.	0.6	7
113	Diagnostic Yield of CT-Guided Percutaneous Transthoracic Needle Biopsy for Diagnosis of Anterior Mediastinal Masses. <i>American Journal of Roentgenology</i> , 2015, 205, 774-779.	1.0	54
114	Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 661-668.	1.2	31
115	Prior cytopenia predicts worse clinical outcome in acute myeloid leukemia. <i>Leukemia Research</i> , 2015, 39, 1034-1040.	0.4	8
116	High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome. <i>Modern Pathology</i> , 2015, 28, 552-563.	2.9	42
117	PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks. <i>Blood</i> , 2015, 126, 56-56.	0.6	28
118	Pediatric-Type Nodal Follicular Lymphoma in Children and Adults Is Nearly Genetically Silent and Biologically Distinct from Typical Follicular Lymphoma. <i>Blood</i> , 2015, 126, 3925-3925.	0.6	0
119	Diverse Clinicopathologic Features in Human Herpesvirus 8-Associated Lymphomas Lead to Diagnostic Problems. <i>American Journal of Clinical Pathology</i> , 2014, 142, 816-829.	0.4	55
120	High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms. <i>Modern Pathology</i> , 2014, 27, 1447-1454.	2.9	24
121	Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. <i>Haematologica</i> , 2014, 99, 821-829.	1.7	61
122	Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results. <i>Blood</i> , 2014, 124, 713-713.	0.6	31
123	Differential regulation of myeloid leukemias by the bone marrow microenvironment. <i>Nature Medicine</i> , 2013, 19, 1513-1517.	15.2	233
124	Erythroleukemia and Its Differential Diagnosis. <i>Surgical Pathology Clinics</i> , 2013, 6, 641-659.	0.7	9
125	Inter-reader variability in follicular lymphoma grading: Conventional and digital reading. <i>Journal of Pathology Informatics</i> , 2013, 4, 30.	0.8	20
126	Effect Of Treatment With The JAK2-Selective Inhibitor Fedratinib (SAR302503) On Bone Marrow Histology In Patients With Myeloproliferative Neoplasms With Myelofibrosis. <i>Blood</i> , 2013, 122, 2823-2823.	0.6	15

#	ARTICLE	IF	CITATIONS
127	Differential Regulation of Myeloid Leukemias by the Bone Marrow Microenvironment. <i>Blood</i> , 2012, 120, 1245-1245.	0.6	1
128	Clinicopathologic Characterization of Acute Myeloid Leukemia and Myelodysplastic Syndrome with Inv(3)(q21q26.2)/t(3;3)(q21;q26.2) Reveals That Complex Karyotype but Not Blast Percentage Is Associated with Poor Survival; A Bone Marrow Pathology Group Study. <i>Blood</i> , 2012, 120, 3847-3847.	0.6	0
129	Chronic myelogenous leukemia in the age of imatinib: assessing response, acceleration, and blast phase. <i>Journal of Hematopathology</i> , 2011, 4, 81-92.	0.2	1
130	Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with CD30-positive lymphocyte-predominant (LP) cells. <i>Journal of Hematopathology</i> , 2011, 4, 175-181.	0.2	11
131	Parathyroid Hormone-Induced Modulation of the Bone Marrow Microenvironment Reduces Leukemic Stem Cells in Murine Chronic Myelogenous-Leukemia-Like Disease Via a TGFbeta-Dependent Pathway. <i>Blood</i> , 2011, 118, 1670-1670.	0.6	1
132	Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. <i>Blood</i> , 2010, 115, 1985-1992.	0.6	97
133	Evidence of Long Latency Periods Prior to Development of Mantle Cell Lymphoma. <i>Blood</i> , 2010, 116, 323-323.	0.6	9
134	Response to Dasatinib In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Correlates with p-Lyn and p-Syk. <i>Blood</i> , 2010, 116, 2457-2457.	0.6	0
135	Immunomodulator agent-related lymphoproliferative disorders. <i>Modern Pathology</i> , 2009, 22, 1532-1540.	2.9	74
136	Niche Induced Myelodysplasia and Secondary Hematopoietic Neoplasia Caused by Deletion of Dicer1 in Osteoprogenitor Cells.. <i>Blood</i> , 2009, 114, 247-247.	0.6	0
137	Evaluation of Bone Marrow Reticulin Formation in Romiplostim-Treated Adult Patients with Chronic Immune Thrombocytopenic Purpura (ITP).. <i>Blood</i> , 2008, 112, 3416-3416.	0.6	2
138	Reactive Versus Neoplastic Bone Marrow: Problems and Pitfalls. <i>Archives of Pathology and Laboratory Medicine</i> , 2008, 132, 587-594.	1.2	14
139	Precursor B Lymphoblastic Lymphoma Restricted to the Central Nervous System: A Case Report. <i>FASEB Journal</i> , 2007, 21, A391.	0.2	0
140	Bone Marrow Reticulin in Patients with Immune Thrombocytopenic Purpura.. <i>Blood</i> , 2006, 108, 3982-3982.	0.6	18
141	Philadelphia Chromosome Positive Acute Myeloid Leukemia: An Aggressive Acute Leukemia with Clinicopathologic Features Distinct from Chronic Myeloid Leukemia in Blast Crisis.. <i>Blood</i> , 2005, 106, 3290-3290.	0.6	0